Should I buy or sell Evaxion Biotech A/S stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EVAX shares. View EVAX analyst ratings or view top-rated stocks .

What is Evaxion Biotech A/S's stock price target for 2024?

2 Wall Street research analysts have issued twelve-month price objectives for Evaxion Biotech A/S's stock. Their EVAX share price targets range from $70.00 to $70.00. On average, they anticipate the company's share price to reach $70.00 in the next year. This suggests a possible upside of 1,641.3% from the stock's current price. View analysts price targets for EVAX or view top-rated stocks among Wall Street analysts .

How have EVAX shares performed in 2024?

Evaxion Biotech A/S's stock was trading at $6.8570 on January 1st, 2024. Since then, EVAX stock has decreased by 41.4% and is now trading at $4.02. View the best growth stocks for 2024 here .

When is Evaxion Biotech A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our EVAX earnings forecast .

How were Evaxion Biotech A/S's earnings last quarter?

Evaxion Biotech A/S (NASDAQ:EVAX) issued its quarterly earnings data on Tuesday, December, 19th. The company reported ($2.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.90) by $0.20.

When did Evaxion Biotech A/S's stock split?

Evaxion Biotech A/S shares reverse split on Monday, January 22nd 2024. The 1-10 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Evaxion Biotech A/S IPO?

(EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Who are Evaxion Biotech A/S's major shareholders?

Evaxion Biotech A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Beacon Capital Management LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EVAX

Evaxion Biotech A/S (EVAX) Stock Price, News & Analysis

$4.02

-0.21 (-4.96%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $4.01
▼
$4.46
50-Day Range: $3.75
▼
$10.65
52-Week Range: $3.36
▼
$18.50

Volume: 73,600 shs
Average Volume: 1.43 million shs
Market Capitalization: $15.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $70.00

Get Evaxion Biotech A/S alerts:

Evaxion Biotech A/S MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1,641.3% Upside
$70.00 Price Target
Short Interest: Healthy
0.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.39
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($8.20) to ($3.70) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.97 out of 5 stars

Medical Sector

420th out of 922 stocks

Biological Products, Except Diagnostic Industry

67th out of 151 stocks

3.3

Analyst's Opinion

Consensus Rating
Evaxion Biotech A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $70.00, Evaxion Biotech A/S has a forecasted upside of 1,641.3% from its current price of $4.02.
Amount of Analyst Coverage
Evaxion Biotech A/S has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.31% of the outstanding shares of Evaxion Biotech A/S have been sold short.
Short Interest Ratio / Days to Cover
Evaxion Biotech A/S has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Evaxion Biotech A/S has recently decreased by 92.49%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Evaxion Biotech A/S does not currently pay a dividend.
Dividend Growth
Evaxion Biotech A/S does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EVAX.

3.0

News and Social Media Coverage

News Sentiment
Evaxion Biotech A/S has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Evaxion Biotech A/S this week, compared to 1 article on an average week.
Search Interest
17 people have searched for EVAX on MarketBeat in the last 30 days.
MarketBeat Follows
8 people have added Evaxion Biotech A/S to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.64% of the stock of Evaxion Biotech A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.58% of the stock of Evaxion Biotech A/S is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Evaxion Biotech A/S are expected to grow in the coming year, from ($8.20) to ($3.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Evaxion Biotech A/S is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Evaxion Biotech A/S is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Evaxion Biotech A/S has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Evaxion Biotech A/S Stock (NASDAQ:EVAX)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.

EVAX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EVAX Stock News Headlines

February 7, 2024 | investing.com

Evaxion Biotech AS (EVAX)

February 7, 2024 | finance.yahoo.com

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.

February 6, 2024 | finanznachrichten.de

Evaxion Biotech: Evaxion Announces Closing of $15 Million Public Offering

February 6, 2024 | finance.yahoo.com

Evaxion Announces Closing of $15 Million Public Offering

February 1, 2024 | msn.com

Evaxion Biotech to raise ~$15M through public offering of shares and warrants

February 1, 2024 | finance.yahoo.com

Evaxion Biotech Announces Pricing of $15 Million Public Offering

January 25, 2024 | msn.com

Evaxion Biotech to develop new vaccines for cancer

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

January 24, 2024 | morningstar.com

ADRs Close Higher, Evaxion Biotech A/S Climbs 113.4%

January 24, 2024 | msn.com

Evaxion stock rallies 120% on AI-based cancer vaccine program

January 24, 2024 | finanznachrichten.de

Evaxion Biotech: Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

January 24, 2024 | marketwatch.com

Evaxion ADSs Rise 17% After ADS Ratio Change

January 24, 2024 | finance.yahoo.com

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

January 22, 2024 | finanznachrichten.de

Evaxion Biotech: Evaxion Announces Completion of ADS Ratio Change

January 22, 2024 | morningstar.com

ADRs End Lower; Evaxion Biotech A/S Drops 45%

January 22, 2024 | finance.yahoo.com

Evaxion Announces Completion of ADS Ratio Change

January 8, 2024 | finance.yahoo.com

Evaxion Announces Plan to Implement ADS Ratio Change

December 21, 2023 | finance.yahoo.com

Evaxion Biotech Announces Closing of Private Placement

December 20, 2023 | benzinga.com

Evaxion Biotech Stock (NASDAQ:EVAX) Earnings Dates and Earning Calls

December 20, 2023 | finanznachrichten.de

Evaxion Biotech: Evaxion Announces Business Update and Third Quarter 2023 Financial Results

December 19, 2023 | benzinga.com

Evaxion Biotech: Q3 Earnings Insights

December 19, 2023 | msn.com

Evaxion Biotech ADS GAAP EPS of -$0.21 misses by $0.01

December 19, 2023 | finance.yahoo.com

Evaxion Announces Business Update and Third Quarter 2023 Financial Results

December 19, 2023 | msn.com

Evaxion Biotech to raise $5.3M via private placement

December 19, 2023 | finance.yahoo.com

Evaxion Biotech Announces Private Placement Financing

November 28, 2023 | finance.yahoo.com

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

See More Headlines

Receive EVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/19/2023
Today: 2/12/2024
Next Earnings (Estimated): 4/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:EVAX
CUSIP: N/A
CIK: 1828253
Web: www.evaxion-biotech.com
Phone: 45-5353-1850
Fax: N/A
Employees: 63
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $70.00
High Stock Price Target: $70.00
Low Stock Price Target: $70.00
Potential Upside/Downside: +1,641.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($9.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -451.63%
Return on Assets: -126.22%

Debt

Debt-to-Equity Ratio: 3.95
Current Ratio: 2.81
Quick Ratio: 2.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.48 per share
Price / Book: 1.16

Miscellaneous

Outstanding Shares: 3,790,000
Free Float: 2,212,000
Market Cap: $15.24 million
Optionable: Optionable
Beta: N/A

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Christian Kanstrup M.Sc. (Age 52)
Chief Executive Officer
Comp: $454k
Mr. Andreas Holm Mattsson (Age 48)
Co-Founder and Chief AI & Culture Officer
Comp: $247k
Dr. Niels Iversen Moller M.D. (Age 45)
Co-Founder, VP of Business & Director
Comp: $120k
Mr. Jesper Nyegaard Nissen M.Sc. (Age 53)
CFO & COO
Comp: $346.97k
Dr. Birgitte Rono Ph.D. (Age 47)
Chief Scientific Officer
Comp: $336k
Dr. Jürgen Langhärig EMBA
Ph.D., Head of Business Development & Member of Advisory Board

Key Competitors

View All Competitors

Institutional Ownership

Beacon Capital Management LLC
Bought 41,752 shares on 1/9/2024
Ownership: 0.173%

View All Institutional Transactions

EVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Evaxion Biotech A/S stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EVAX shares.
View EVAX analyst ratings or view top-rated stocks.
What is Evaxion Biotech A/S's stock price target for 2024?: 2 Wall Street research analysts have issued twelve-month price objectives for Evaxion Biotech A/S's stock. Their EVAX share price targets range from $70.00 to $70.00. On average, they anticipate the company's share price to reach $70.00 in the next year. This suggests a possible upside of 1,641.3% from the stock's current price.
View analysts price targets for EVAX or view top-rated stocks among Wall Street analysts.
How have EVAX shares performed in 2024?: Evaxion Biotech A/S's stock was trading at $6.8570 on January 1st, 2024. Since then, EVAX stock has decreased by 41.4% and is now trading at $4.02.
View the best growth stocks for 2024 here.
When is Evaxion Biotech A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our EVAX earnings forecast.
How were Evaxion Biotech A/S's earnings last quarter?: Evaxion Biotech A/S (NASDAQ:EVAX) issued its quarterly earnings data on Tuesday, December, 19th. The company reported ($2.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.90) by $0.20.

When did Evaxion Biotech A/S's stock split?: Evaxion Biotech A/S shares reverse split on Monday, January 22nd 2024. The 1-10 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
When did Evaxion Biotech A/S IPO?: (EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.
Who are Evaxion Biotech A/S's major shareholders?: Evaxion Biotech A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Beacon Capital Management LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Evaxion Biotech A/S?: Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVAX) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial